杏林製薬の株価時系列
日付 | 始値 | 高値 | 安値 | 終値 | 前日比 | 騰落率 | 出来高 |
---|---|---|---|---|---|---|---|
2018/02/21 | 2,081 | 2,084 | 2,060 | 2,066 | -13 | -0.6% | 200,200 |
2018/02/20 | 2,085 | 2,086 | 2,071 | 2,079 | -6 | -0.3% | 139,100 |
2018/02/19 | 2,052 | 2,088 | 2,048 | 2,085 | +56 | +2.8% | 191,800 |
2018/02/16 | 2,016 | 2,044 | 2,016 | 2,029 | +13 | +0.6% | 205,700 |
2018/02/15 | 2,010 | 2,022 | 2,007 | 2,016 | +10 | +0.5% | 155,900 |
2018/02/14 | 2,025 | 2,042 | 1,995 | 2,006 | -3 | -0.1% | 338,900 |
2018/02/13 | 2,052 | 2,054 | 2,003 | 2,009 | -30 | -1.5% | 361,600 |
2018/02/09 | 2,063 | 2,077 | 2,031 | 2,039 | -73 | -3.5% | 264,000 |
2018/02/08 | 2,119 | 2,133 | 2,107 | 2,112 | +18 | +0.9% | 298,500 |
2018/02/07 | 2,080 | 2,134 | 2,075 | 2,094 | +35 | +1.7% | 536,000 |
2018/02/06 | 2,040 | 2,075 | 2,040 | 2,059 | +3 | +0.1% | 582,300 |
2018/02/05 | 2,080 | 2,099 | 2,039 | 2,056 | -34 | -1.6% | 533,200 |
2018/02/02 | 2,096 | 2,099 | 2,081 | 2,090 | -12 | -0.6% | 155,000 |
2018/02/01 | 2,075 | 2,102 | 2,069 | 2,102 | +26 | +1.3% | 202,100 |
2018/01/31 | 2,097 | 2,106 | 2,076 | 2,076 | -24 | -1.1% | 248,800 |
2018/01/30 | 2,106 | 2,116 | 2,095 | 2,100 | -1 | ±0% | 185,400 |
2018/01/29 | 2,106 | 2,112 | 2,096 | 2,101 | ±0 | ±0% | 136,100 |
2018/01/26 | 2,093 | 2,113 | 2,093 | 2,101 | +6 | +0.3% | 122,000 |
2018/01/25 | 2,095 | 2,106 | 2,089 | 2,095 | -7 | -0.3% | 123,400 |
2018/01/24 | 2,093 | 2,105 | 2,093 | 2,102 | +9 | +0.4% | 142,300 |
2018/01/23 | 2,088 | 2,105 | 2,088 | 2,093 | +20 | +1% | 147,600 |
2018/01/22 | 2,070 | 2,073 | 2,058 | 2,073 | +14 | +0.7% | 166,900 |
2018/01/19 | 2,072 | 2,077 | 2,054 | 2,059 | -15 | -0.7% | 191,600 |
2018/01/18 | 2,105 | 2,110 | 2,074 | 2,074 | -26 | -1.2% | 200,900 |
2018/01/17 | 2,112 | 2,113 | 2,099 | 2,100 | -14 | -0.7% | 150,500 |
2018/01/16 | 2,136 | 2,138 | 2,112 | 2,114 | -22 | -1% | 122,000 |
2018/01/15 | 2,141 | 2,149 | 2,133 | 2,136 | +12 | +0.6% | 104,100 |
2018/01/12 | 2,183 | 2,197 | 2,123 | 2,124 | -66 | -3% | 251,800 |
2018/01/11 | 2,184 | 2,196 | 2,167 | 2,190 | +2 | +0.1% | 249,900 |
2018/01/10 | 2,190 | 2,199 | 2,184 | 2,188 | -6 | -0.3% | 160,900 |
2018/01/09 | 2,176 | 2,195 | 2,159 | 2,194 | +17 | +0.8% | 220,000 |
2018/01/05 | 2,151 | 2,178 | 2,134 | 2,177 | +17 | +0.8% | 162,700 |
2018/01/04 | 2,117 | 2,164 | 2,117 | 2,160 | +48 | +2.3% | 277,500 |
2017/12/29 | 2,113 | 2,139 | 2,093 | 2,112 | -51 | -2.4% | 393,800 |
2017/12/28 | 2,162 | 2,175 | 2,158 | 2,163 | -1 | ±0% | 77,300 |
2017/12/27 | 2,183 | 2,184 | 2,162 | 2,164 | -10 | -0.5% | 52,500 |
2017/12/26 | 2,175 | 2,184 | 2,168 | 2,174 | +1 | ±0% | 99,000 |
2017/12/25 | 2,184 | 2,185 | 2,167 | 2,173 | +4 | +0.2% | 75,400 |
2017/12/22 | 2,164 | 2,184 | 2,154 | 2,169 | -8 | -0.4% | 122,200 |
2017/12/21 | 2,147 | 2,184 | 2,142 | 2,177 | +29 | +1.4% | 172,300 |
2017/12/20 | 2,143 | 2,156 | 2,140 | 2,148 | +4 | +0.2% | 102,600 |
2017/12/19 | 2,147 | 2,152 | 2,127 | 2,144 | -1 | ±0% | 172,400 |
2017/12/18 | 2,144 | 2,147 | 2,137 | 2,145 | +20 | +0.9% | 89,700 |
2017/12/15 | 2,118 | 2,126 | 2,090 | 2,125 | -5 | -0.2% | 252,700 |
2017/12/14 | 2,155 | 2,161 | 2,127 | 2,130 | -20 | -0.9% | 172,800 |
2017/12/13 | 2,140 | 2,159 | 2,138 | 2,150 | +27 | +1.3% | 131,100 |
2017/12/12 | 2,126 | 2,133 | 2,123 | 2,123 | +1 | ±0% | 108,800 |
2017/12/11 | 2,121 | 2,132 | 2,117 | 2,122 | +1 | ±0% | 122,700 |
2017/12/08 | 2,068 | 2,124 | 2,068 | 2,121 | +8 | +0.4% | 217,900 |
2017/12/07 | 2,083 | 2,115 | 2,083 | 2,113 | +31 | +1.5% | 198,400 |
1651~
1700
件表示中 / 3586件
類似銘柄と比較する
現在ご覧いただいている「杏林製薬」と類似性の高い銘柄をピックアップ。投資家が注目しているデータで比較できるようになっています。銘柄選びの参考情報としてご活用ください。
銘柄名 | 最低購入代金 | 売上高 成長率 |
経常 増益率 |
配当 利回り |
PER | PBR | 直近のチャート | 特色 |
---|---|---|---|---|---|---|---|---|
杏林製薬 | 149,900円 | +3.2% | +4.5% | 3.47% | 17.22倍 | 0.66倍 |
|
医薬中堅。柱のぜんそく薬、呼吸器アレルギー薬は下期に比重。消化器領域育成。後発品も |
ゼリア新薬 | 224,400円 | +13.6% | +29.2% | 2.05% | 11.64倍 | 1.12倍 |
|
製薬中堅。医療用は消化器系中心。滋養強壮剤「ヘパリーゼ」も柱。スイス企業買収で海外展開 |
ネクセラファーマ | 113,200円 | +197.7% | - | 0.00% | 46.26倍 | 1.48倍 |
|
創薬ベンチャー老舗。買収で成長。英国の創薬事業に日本が柱の後期治験・製造販売事業加わる |
JCRファーマ | 72,400円 | -3.7% | -36.7% | 2.76% | 23.84倍 | 1.56倍 |
|
ヒト成長ホルモン製剤が主力、バイオ後続品も成長。希少疾病のバイオ新薬開発にも取り組む |
栄研化 | 209,200円 | +0.4% | -8.4% | 2.53% | 27.65倍 | 1.57倍 |
|
臨床検査薬大手。便潜血検査試薬(FIT)はシェア7割。尿検査(ウロ)、遺伝子検査も育成 |
市場注目の銘柄
チャート関連のコラム